Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial.
- New drug combination shows promise as powerful treatment for AML
- Childhood neglect leaves generational imprint
- New approach emerges to better classify, treat brain tumors
- Certain parenting behaviors associated with positive changes in well-being during COVID-19 pandemic
- Do children view punishment as rehabilitative? A new study takes a look